Spectral AI, Inc. (NASDAQ:MDAI - Free Report) - Equities researchers at Northland Securities raised their FY2027 earnings estimates for shares of Spectral AI in a research note issued to investors on Tuesday, October 27th. Northland Securities analyst L. Horton now anticipates that the company will post earnings per share of ($0.34) for the year, up from their prior estimate of ($0.44). Northland Securities currently has a "Strong-Buy" rating on the stock. The consensus estimate for Spectral AI's current full-year earnings is ($0.50) per share.
Other research analysts also recently issued reports about the company. Weiss Ratings upgraded Spectral AI from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday. Wall Street Zen upgraded Spectral AI from a "sell" rating to a "hold" rating in a research note on Saturday, September 12th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Spectral AI currently has a consensus rating of "Moderate Buy" and an average target price of $4.00.
Read Our Latest Stock Report on Spectral AI
Spectral AI Trading Up 2.0%
Shares of MDAI opened at $1.56 on Thursday. Spectral AI has a 12 month low of $1.18 and a 12 month high of $2.97. The stock has a fifty day moving average price of $1.59 and a 200-day moving average price of $1.70. The firm has a market cap of $50.22 million, a PE ratio of -4.46 and a beta of 1.21.
Spectral AI (NASDAQ:MDAI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. The firm had revenue of $3.52 million for the quarter, compared to the consensus estimate of $4.17 million.
About Spectral AI
(
Get Free Report)
Spectral AI, Inc is a medical diagnostic technology company focused on using artificial intelligence and advanced imaging to support earlier, more objective assessment of wound healing. The company develops predictive diagnostic systems intended to help clinicians evaluate wounds and make treatment decisions.
Its principal product is the DeepView System, a noninvasive imaging and artificial intelligence platform designed to assess burn wounds and predict the likelihood that injured tissue will heal without surgical intervention.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spectral AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spectral AI wasn't on the list.
While Spectral AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.